<DOC>
	<DOCNO>NCT01274572</DOCNO>
	<brief_summary>This study conduct assess monitor immune response patient minimally symptomatic asymptomatic hormone refractory prostate cancer receive Provenge® ( Sipuleucel-T ) therapy part standard care treatment regimen .</brief_summary>
	<brief_title>Blood Immune Response Provenge® HRPC</brief_title>
	<detailed_description>This study conduct assess monitor immune response patient minimally symptomatic asymptomatic hormone refractory prostate cancer receive Provenge® ( Sipuleucel-T ) therapy part standard care treatment regimen . The trial involve collection additional blood sample purpose monitor immune response . These sample take 7 time point , patient receive Provenge® ( Sipuleucel-T ) . There study-specific procedure perform ( blood draw ) use investigational agent study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients plan receive standard care Provenge® ( SipuleucelT ) primary physican 's office .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>